Health
Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward – TCTMD
DREAM-HF provides hints of an anti-inflammatory effect and benefits beyond the heart, setting up future trials.
Targeted injection of mesenchymal precursor cells (MPCs) into the myocardium is safe but does not reduce recurrent nonfatal decompensated heart failure (HF) events in patients with chronic HF with reduced ejection fraction (HFrEF), the randomized DREAM-HF…
Continue Reading
-
Noosa News16 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business20 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today
-
General15 hours agoRescuers pull children from the rubble of Indonesian boarding school collapse
-
Noosa News18 hours agoAnother whale calf caught in Noosa nets